Business
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the
About this update from Ainos, Inc.
[{"type":"text","content":"SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has signed a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. (Taiwan) (\"Swiss Pharma\"). Pursuant to the agreement, Swiss Pharma will test, manufacture, and package the Company's VELDONA \"GMP Clinical Batch\" and \"GMP Commercial Batch\" product candidates for the Company's planned clinical trials under both Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice (\"PIC/S GMP\") and U.S. Food & Drug Administration (\"U.S. FDA\") Current Good Manufacturing Practice regulations.The Company plans to submit an Investigational New Drug (\"IND\") application for a Phase 2 Study to the U.S. FDA by the end of this year.Following previous results from preclinical studies of its VELDONA formulation against COVID-19 in June 2022, Ainos initiated \"A Multicenter, Randomized, Parallel, Phase II Study to Evaluate the Efficacy of VELDONA® in Patients with Mild COVID-19\" in Taiwan.The Company's prior studies of its VELDONA, interferon-based drug platform, have focused on various viral infections. The Company has previously conducted promising clinical studies on influenza (https://onlinelibrary.wiley.com/doi/10.1111/irv.12094) and the common cold (https://clinicaltrials.gov/ct2/show/NCT00895947?term=Amarillo+Biosciences%2C+Inc.&draw=2&rank=3). The Company plans to further its VELDONA program with the initiation of a Phase 2 study for thrombocytopenia and Phase 3 study for Sjögren's syndrome in 2023.Chun-Hsien Tsai, Chairman and Chief Executive Officer of Ainos, commented, \"Our relationship with Swiss Pharma forms a strong foundation for our plans to develop VELDONA product candidates. We anticipate our relationship with Swiss Pharma will enable us to effectively increase our manufacturing capabilities for VELDONA for our clinical trials, including testing, quality inspection, labeling, and packaging.\"About Ainos, Inc.Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatm...